stockrowSpyre Therapeutics, Inc.
SYRE Healthcare Biotechnology
Spyre Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $886,000.00, down 62.0% from fiscal 2022.
- EPS
- −624.8%
- Free cash flow
- −108.8%
Quarter to September 2026, against a year earlier
Follow SYRE
Alert me
Spyre Therapeutics, Inc. (SYRE) Book value per share
Spyre Therapeutics, Inc.'s book value per share at the end of fiscal 2025 was 11.2×, unchanged from fiscal 2024. At the end of the quarter to 30 September 2026 it was 11.9×. Over the past ten years it has ranged from 11.0× (fiscal 2024) to 1,504× (fiscal 2015); the current reading is higher than 18% of that period. Spyre Therapeutics, Inc. ranks 68th of 611 Biotechnology companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | 11.2× | 1.41% |
| FY2024 | 11.0× | (58.73%) |
| FY2023 | 26.7× | 78.79% |
| FY2022 | 14.9× | (53.25%) |
| FY2021 | 31.9× | (51.27%) |
| FY2020 | 65.5× | 39.32% |
| FY2019 | 47.0× | (41.93%) |
| FY2018 | 81.0× | (2.68%) |
| FY2017 | 83.2× | (48.25%) |
| FY2016 | 161× | (89.31%) |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Sep 2026 | 11.9× | (8.48%) |
| Jun 2026 | 13.0× | 52.18% |
| Mar 2026 | 8.5× | (23.52%) |
| Dec 2025 | 11.2× | 48.22% |
| 43 more quarters | Free account |
Against its own ten years
Book value per share against peers
| Company | Book value per share |
|---|---|
| KRYS Krystal Biotech, Inc. compare | 48.5× |
| MDGL Madrigal Pharmaceuticals, Inc. compare | 21.4× |
| PTGX Protagonist Therapeutics, Inc. compare | 12.8× |
| SYRE Spyre Therapeutics, Inc. | 11.9× |
| TWST Twist Bioscience Corporation compare | 7.1× |
| TGTX TG Therapeutics, Inc. compare | 4.3× |
| CYTK Cytokinetics, Incorporated compare | 0.0× |
| CAI Caris Life Sciences,�Inc. compare | 0.0× |
| IBRX ImmunityBio, Inc. compare | −1.0× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))
More on SYRE
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement